Physician profile
Christopher Dyer
NPI 1548203433
$826.80
in general payments reported to CMS, 2019-2025
12 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.90 · 2020: $12.16 · 2021: $28.73 · 2022: $423 · 2023: $199 · 2024: $15.60 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $412.55 | 2022-2025 | Proclaim, Eterna |
| Forte Bio-Pharma LLC | $89.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.31 | 2021-2022 | |
| Abbvie INC. | $47.60 | 2023-2024 | Qulipta |
| Pfizer INC. | $46.52 | 2020-2023 | |
| Scilex Pharmaceuticals INC. | $35.59 | 2019-2023 | Ztlido |
| Vertex Pharmaceuticals Incorporated | $23.94 | 2025 | |
| Ibsa Pharma INC. | $23.11 | 2023 | Tirosint, Licart |
| Trevena, INC. | $22.63 | 2023 | Olinvyk |
| Sanofi-Aventis U.S. LLC | $17.88 | 2022 | |
| Painteq LLC | $17.27 | 2022 | |
| Shionogi INC | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.